Company Interview / It's all systems go for Remplir's US rollout

Orthocell (ASX: OCC) CEO and co-founder Paul Anderson explains how the biotech's collagen nerve wrap treatment, Remplir, is progressing. Orthocell is gearing up for a significant commercial launch in the US, with Remplir receiving the go-ahead from the FDA.

The treatment is being tested for peripheral nerve repair and is showing promising results when it comes to nerve repair.

Orthocell, a regenerative medicine company, develops and commercialises cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally. The treatment is being tested for peripheral nerve repair and is showing promising results when it comes to nerve repair.

Paul Anderson highlights that Orthocell's proprietary manufacturing process enables the production of over 100,000 units, with logistics partnerships ensuring smooth distribution. With a robust sales model, 12 distributors have been secured to cover 21 states, Anderson says Orthocell is ready to take on the US opportunity.

*The information contained in this event is general in nature and is not intended as advice. 

Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD